PLUVICTO

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• 3 steps for taking on Novartis in radiopharma: Curium up first
  To successfully challenge Novartis on two planned fronts, Curium will need to overcome the unique challenges posed by radiopharmaceutical supply to get products to patients and win market share.
  biospace · 5d ago
• Novartis bets up to $900M for radioligand therapy from China’s BoomRay
  Novartis is the current radiopharma leader with two FDA-approved therapies in Pluvicto and Lutathera.
  biospace · 10d ago
• Novartis secures new radioligand in $900M deal as competition strengthens
  As an imposing new competitor begins to take shape, radiopharma leader Novartis has beefed up its pipeline by licensing a preclinical radioligand therapy from a specialist Chinese biotech.
  fiercebiotech · 11d ago
• Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
  Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
  biospace · 12d ago
• Sleuth forecasts 2027 jump in Western license deals for Chinese radioligand therapies
  Deals for Chinese radiopharmaceutical assets have been rare to date and there is a limited pool of potential Western buyers available, Sleuth said.
  biospace · 12d ago
• Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
  Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…
  biospace · 12d ago
• Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
  Worth $1.65 billion up front, the deal combines two large pipelines and manufacturing networks, helping Telix potentially “corner the industry” for radiopharmaceuticals, one analyst wrote.
  biopharma_dive · 12d ago
• Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
  Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera and a radiopharmaceutical supply network.
  fiercebiotech · 13d ago
• Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
  Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
  biospace · 23d ago
• A winner, a loser, and a mid-stage signal from a major cardiology research conference
  The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from Morning Rounds
  stat · 1mo ago